Tagged with PR

Pharma The following chart illustrates the various bottlenecks restraining the development of France’s pharmaceutical industry, including lack of investment, fewer new molecules than other European countries, disappointing performance in biological drugs, and long waiting times for drug approval. Click here to read more articles and interviews from France, and to download the…

Pharma Following regulatory changes, CSL Behring is now able to offer plasma fractionation and purification services to Italy’s public healthcare sector for the first time. General manager Oliver Schmitt discusses the added value and savings CSL Behring can offer in this service segment and the benefits its newest generation of innovative…

Pharma Stephane Baudry not only provides insight into his holding company EHDH (European Health Care Distribution Holding), the spectacular growth of affiliate EuroTransPharma and the developments underway for his other subsidiaries Transport Dufour and Ciblex Express, but also shares his views on the goal for the European Association for Logistics and…

Pharma Providing universal health coverage to the nation’s roughly 10 million citizens, Hungary’s National Health Insurance Fund (OEP) has one of the most comprehensive and complex structures in Europe. The organization’s Head of Pricing Support, Dr. Judit Bidló discusses the current mechanisms governing pharmaceutical reimbursements in Hungary, while also identifying the…

Pharma PwC Italy’s Rodrigue G. Schübelin talks maintaining Italy’s impressive growth in pharma production, R&D incentives, public-private collaboration, and PwC’s role within the Italian healthcare ecosystem. Italy’s pharmaceutical production increased by 38 percent from 2009 to 2014; what steps does the industry need to take to keep performing at this level?…

Pharma Hungary’s Minister of Foreign Affairs and Trade Péter Szijjártó highlights the significant role that foreign direct investments have played in developing the country’s healthcare and life science sector, while detailing the nation’s ambitions of not only pivoting into Europe’s hub for production, but also innovation. With over a century-long tradition,…

Pharma GSK Hungary’s Claire Roger discusses the value of ethical promotion both in improving transparency and benefiting all stakeholders. She further describes the strategic role and economic impact of GSK’s vaccine plant in Gödöllő and growth opportunities in HIV. Given that you’ve only recently arrived in May 2015, Claire, what priorities have been at the…

Pharma Róbert Ésik, President of the Hungarian Investment Promotion Agency (HIPA), shares his insights into what makes Hungary such an attractive destination for foreign direct investment and ways that the agency will work to increase the amount of FDI in the country. He also discusses the unique Hungarian business culture and…

Pharma Veronika Ferencz, Sales and Marketing Director for Exeltis Hungary, discusses the evolving and expanding footprint of the company in Hungary, the challenges strict regulations on food supplements are causing, as well as the need for better recognition of women’s health as a therapeutic area. She also reflects on her own…

Pharma The leadership of Meditop discuss their history as the first non-privatized, private Hungarian pharmaceutical company, their ongoing strategies for growth in the country, and their evolving portfolio abroad. They also discuss the complexities of the Hungarian healthcare and pharmaceutical market and give an overview of their past challenges and current…

Pharma The country manager for CSL Behring Czech Republic reviews his tremendous success in the country, averaging 50 percent annual growth since 2011. Furthermore, he explains why the current reimbursement system is beneficial for them although it results in high price pressure for innovative pharmaceutical treatments. The question on everybody’s lips…

Pharma Soneas MD Jozsef Repasi discusses the shift back towards Central and Eastern Europe for contract manufacturing services, the company’s growth since separating from Ubichem, and his ambitions for Soneas to become a fully integrated, end-to-end service provider. As an introduction for our readers, can you please shed some insight into…